AI-generated summary
This retrospective study at a Brazilian referral service reviewed 148 children and adolescents receiving chemotherapy who got prophylactic photobiomodulation with a 660 nm laser. The authors report lower oral mucositis severity in acute lymphoblastic leukaemia and osteosarcoma patients who received the therapy, and higher risk among methotrexate users without it. The retrospective design and lack of a randomized control group limit causal conclusions.
- Participants
- 148
- Who or what was studied
- Children and adolescents (17 years or younger) receiving chemotherapy or undergoing haematopoietic stem cell transplantation at a Brazilian paediatric oncology referral service
- Wavelengths
- 660 nm
- Limits stated in the abstract
- The study is retrospective and does not describe a randomized control group, so associations cannot be taken as proof of causation.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 660 nm
- Power
- 100 mW
- Total energy
- 2 J
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation therapy, Photobiomodulation, Oral mucositis, Laser, GRADE. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.